If you blinked, you might have missed it. Liminatus Pharma (LIMN) — a biopharmaceutical company with a market cap of just $8.43 million — saw its shares spike 79.34% to $0.34 in after-hours trading Thursday. That's a big move for a stock that closed the regular session down 1.16% at $0.19.

The catalyst? A merger agreement with InnocsAI LLC, a Delaware-based limited liability company. Under the deal, InnocsAI members will receive 1.6 billion shares at $0.20 per share, plus contingent value rights representing 20% of net proceeds from future asset exits. That's a lot of shares for a company with only about 44.8 million shares outstanding currently.

Here's where it gets interesting: Liminatus's CEO, Chris Kim, also controls Valetudo Therapeutics LLC, which is a member of InnocsAI. So the deal has some insider flavor — Kim is essentially on both sides of the table.

The merger brings a clinical-stage oncology portfolio into Liminatus. That includes IBC101, a CD19xCD22 bivalent CAR-T candidate that's already been authorized for a Phase 1/2a study in South Korea, plus a preclinical solid tumor program called INC101. So there's real science here, but it's early-stage.

The deal isn't done yet. It's subject to shareholder approval and SEC review, with a termination deadline of December 31. Liminatus itself went public through a SPAC merger with Iris Acquisition Corp back in 2022 — a path that's become less common but still pops up.

Now, let's talk about the stock's recent history, because it's been rough. LIMN has a 52-week high of $33.66 and a 52-week low of $0.16. It's currently trading near that low. Over the past 12 months, the stock has dropped 96.95%. The Relative Strength Index (RSI) sits at 42.16, which is in neutral-to-bearish territory. MarketDash's stock rankings indicate a negative price trend across all time frames.

So what does this all mean? The after-hours surge is a classic reaction to a transformative event — a merger that could fundamentally change the company's trajectory. But the stock's steep decline and weak positioning suggest continued pressure. Elevated risk is the name of the game here, and investors will want to see clear recovery signals before confidence returns.

For now, Liminatus Pharma is a tiny biotech with a big after-hours move, a complex merger, and a lot of questions still unanswered.